509 related articles for article (PubMed ID: 35287591)
21. Prognostic value of prognostic nutritional index and systemic immune-inflammation index in patients with osteosarcoma.
Huang X; Hu H; Zhang W; Shao Z
J Cell Physiol; 2019 Aug; 234(10):18408-18414. PubMed ID: 30891768
[TBL] [Abstract][Full Text] [Related]
22. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
23. The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma.
Zhang H; Shang X; Ren P; Gong L; Ahmed A; Ma Z; Ma R; Wu X; Xiao X; Jiang H; Tang P; Yu Z
J Cell Physiol; 2019 Feb; 234(2):1794-1802. PubMed ID: 30070689
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial.
Tian Y; Yang P; Guo H; Liu Y; Zhang Z; Ding P; Zheng T; Deng H; Ma W; Li Y; Fan L; Zhang Z; Wang D; Zhao X; Tan B; Liu Y; Zhao Q
Int J Surg; 2023 Dec; 109(12):4000-4008. PubMed ID: 37678277
[TBL] [Abstract][Full Text] [Related]
25. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial.
Wei J; Lu X; Liu Q; Fu Y; Liu S; Li L; Liu F; Fan X; Yang J; Yang Y; Zhao Y; Guan W; Liu B
Cancer Manag Res; 2022; 14():2007-2015. PubMed ID: 35747712
[TBL] [Abstract][Full Text] [Related]
27. The Relationship Between Preoperative Systemic Immune Inflammation Index and Prognostic Nutritional Index and the Prognosis of Patients With Alveolar Hydatid Disease.
Ren B; Chen X; Lei P; Hou L; Wang H; Zhou Y; Ren L; Fan H; Wang Z; Yuan J
Front Immunol; 2021; 12():691364. PubMed ID: 34248983
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Patients with HCC.
Wang D; Hu X; Xiao L; Long G; Yao L; Wang Z; Zhou L
J Gastrointest Surg; 2021 Feb; 25(2):421-427. PubMed ID: 32026332
[TBL] [Abstract][Full Text] [Related]
29. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
Wang Y; Cheng X; Cui YH; Hou J; Ji Y; Sun YH; Shen ZB; Liu FL; Liu TS
BMC Cancer; 2018 Jun; 18(1):702. PubMed ID: 29954358
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Postoperative FOLFOX
Yin X; Fang T; Wang Y; Li C; Wang Y; Zhang D; Xue Y
Front Oncol; 2020; 10():584772. PubMed ID: 33425738
[TBL] [Abstract][Full Text] [Related]
31. The Prognostic Value of the Prognostic Nutritional Index in Patients with Advanced or Metastatic Gastric Cancer Treated with Immunotherapy.
Pan Y; Ma Y; Dai G
Nutrients; 2023 Oct; 15(19):. PubMed ID: 37836573
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
Wang Y; Zhuang RY; Yu YY; Yu S; Hou J; Ji Y; Sun YH; Shen KT; Shen ZB; Liu FL; Zhao NQ; Liu TS
Oncotarget; 2016 Nov; 7(46):76298-76307. PubMed ID: 27602586
[TBL] [Abstract][Full Text] [Related]
33. Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy.
Huai Q; Luo C; Song P; Bie F; Bai G; Li Y; Liu Y; Chen X; Zhou B; Sun X; Guo W; Gao S
Cancer Sci; 2023 Dec; 114(12):4484-4498. PubMed ID: 37731264
[TBL] [Abstract][Full Text] [Related]
34. Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer.
Yamaguchi O; Kaira K; Imai H; Mouri A; Shiono A; Miura Y; Hashimoto K; Kobayashi K; Kagamu H
Oncology; 2024; 102(3):271-282. PubMed ID: 37725914
[TBL] [Abstract][Full Text] [Related]
35. Immune-inflammatory-nutritional status predicts oncologic outcomes after radical cystectomy for urothelial carcinoma of bladder.
Teke K; Avci IE; Cinar NB; Baynal EA; Bosnali E; Polat S; Yilmaz H; Kara O; Dillioglugil O
Actas Urol Esp (Engl Ed); 2023 Sep; 47(7):430-440. PubMed ID: 36731820
[TBL] [Abstract][Full Text] [Related]
36. Predictive value of pre-operative prognostic nutritional index and systemic immune-inflammation index for efficacy and survival in patients with non-small cell lung cancer undergoing neoadjuvant chemotherapy.
Lan J; Lin W; Lai Y; Zhang J
Am J Transl Res; 2024; 16(5):2024-2033. PubMed ID: 38883356
[TBL] [Abstract][Full Text] [Related]
37. Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study.
Zheng F; Meng Q; Zhang L; Chen J; Zhao L; Zhou Z; Liu Y
World J Surg Oncol; 2023 Jul; 21(1):198. PubMed ID: 37420219
[TBL] [Abstract][Full Text] [Related]
38. Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy.
Chen L; Yan Y; Zhu L; Cong X; Li S; Song S; Song H; Xue Y
Cancer Manag Res; 2017; 9():849-867. PubMed ID: 29276407
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy and tolerability of first-line treatments for untreated, HER2-negative, advanced gastric cancer: systematic review and network meta-analysis.
Cai T; Liang L; Zhao X; Lin C; Li D; Zheng J
Crit Rev Oncol Hematol; 2024 Jan; 193():104216. PubMed ID: 38029945
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD-1 inhibitor therapy.
Fang Q; Yu J; Li W; Luo J; Deng Q; Chen B; He Y; Zhang J; Zhou C
Clin Exp Pharmacol Physiol; 2023 Feb; 50(2):178-190. PubMed ID: 36419356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
